Clinical Trials Sponsored by PhaseBio Pharmaceuticals Inc

Total 4952 results

PhaseBio Pharmaceuticals Inc.

Completed

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

Heart Failure

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (VANGARD)

Pneumonia | Respiratory Failure | Respiratory Insufficiency | COVID 19 | Acute Respiratory Distress Syndrome | SARS-CoV-2 | Coronavirus | Cytokine Storm | Pulmonary Edema | Cardiac Event | Respiratory Complication | Cardiac Dysfunction | Hypoxemic Respiratory Failure | Hypoxic Respiratory Failure | Cardiac Failure | Cardiac... and other conditions

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

Type 2 Diabetes Mellitus

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (VIP)

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

Healthy

United States
PhaseBio Pharmaceuticals Inc.

Completed

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

Healthy

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
PhaseBio Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend)

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Diabetes Mellitus, Type 2

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Korea University Guro Hospital
Pharmbio Korea Inc.

Not yet recruiting

Intravenous Iron Infusion on Chemotherapy-induced Anemia

Colon Cancer | Chemotherapeutic-Induced Anemia
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (IGNITE1)

Complicated Intra-abdominal Infections

United States, France, Ukraine, Argentina, Bulgaria, Romania, South Africa, Germany, Estonia, Russian Federation, Lithuania, Czechia, Latvia
Tetraphase Pharmaceuticals, Inc.

Completed

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infection

United States, Latvia, Lithuania, Romania, India, Bulgaria
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (IGNITE4)

Complicated Appendicitis | Complicated Intra-abdominal Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
Tetraphase Pharmaceuticals, Inc.

Completed

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Normal Healthy Subjects
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

cUTI

United States, Latvia, Poland, Czechia, Romania, Ukraine, Russian Federation, Georgia, Colombia, Bulgaria, Estonia, Greece, Hungary, Israel, Italy, Mexico, Moldova, Republic of, South Africa
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (IGNITE3)

Complicated Urinary Tract Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Hungary, Austria, Slovakia, Latvia, Moldova, Republic of, Georgia
Tetraphase Pharmaceuticals, Inc.

Completed

A Safety and PK Study of IV Eravacycline

Bacterial Infections

United States
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

Chronic Idiopathic Constipation

United States
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

Osteo Arthritis of the Knee

United States
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

TOURETTE SYNDROME

United States
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD)

Tardive Dyskinesia

United States, Poland, Czechia, Slovakia
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Recruiting

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Major Depressive Disorder

United States

Clinical Trials Sponsored by PhaseBio Pharmaceuticals Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations